Hypobaric-hypoxia-induced pulmonary damage in rats ameliorated by antioxidant erdosteine.
Free radical-mediated injury to lung and pulmonary vasculature is an important mechanism in hypoxia-induced lung damage. In this study, we aimed to investigate the potential protective effects of erdosteine as an antioxidant agent on hypobaric hypoxia-induced pulmonary hypertension. Adult male rats were assigned randomly to three groups. The first group of rats was exposed to hypobaric-hypoxia and the second group was treated with erdosteine (20mg/kg, daily) for 2 weeks, during which time they were in a hypoxic chamber. These groups were compared with normoxic controls. All rats were sacrificed after 2 weeks. The hypoxia-induced increase in right ventricle to left ventricle plus septum weight ratio (from 0.20+/-0.01 to 0.26+/-0.01) was reduced significantly in the erdosteine-treated group (0.23+/-0.01). Malondialdehyde levels were elevated (from 0.33+/-0.11 to 0.59+/-0.02) and total antioxidant status was not changed significantly (from 1.77+/-0.42 to 2.61+/-0.23) by hypoxia. In contrast to the hypoxia-exposed group, malondialdehyde levels were significantly decreased in the erdosteine-treated group (0.37+/-0.02). Total antioxidant status (4.03+/-0.22) was significantly higher in erdosteine-treated rats when compared to non-treated rats. Histopathological examination demonstrated that erdosteine prevented inflammation and protected lung parenchyma and pulmonary endothelium of hypoxia-exposed rats.
Uzun
Ozge
O
Department of Pharmacology, Düzce School of Medicine, University of Abant Izzet Baysal, Düzce, 81620 Konuralp-Turkey. drozgeuzun@yahoo.com
Balbay
Oner
O
Comunoğlu
Nil Ustündağ
NU
Yavuz
Ozlem
O
Nihat Annakkaya
Ali
A
Güler
Selver
S
Silan
Coşkun
C
Erbaş
Mete
M
Arbak
Peri
P
D000818:Animals; D000911:Antibodies, Monoclonal / Q000032:analysis; D000975:Antioxidants / Q000378:metabolism / Q000494:pharmacology*; D001273:Atmosphere Exposure Chambers; D001274:Atmospheric Pressure; D042783:Endothelial Cells / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D006400:Hematocrit; D006470:Hemorrhage / Q000517:prevention & control; D006976:Hypertension, Pulmonary / Q000188:drug therapy / Q000503:physiopathology; D017380:Hypertrophy, Right Ventricular / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D000860:Hypoxia / Q000503:physiopathology*; D007150:Immunohistochemistry; D008168:Lung / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology; D008315:Malondialdehyde / Q000378:metabolism; D011651:Pulmonary Artery / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D011897:Random Allocation; D051381:Rats; D013864:Thioglycolates / Q000378:metabolism / Q000494:pharmacology*; D013876:Thiophenes / Q000378:metabolism / Q000494:pharmacology*
D000911:Antibodies, Monoclonal; D000975:Antioxidants; D013864:Thioglycolates; D013876:Thiophenes; D008315:Malondialdehyde; C048498:erdosteine